Skip to main content
TipRanks
Go Ultimate75% OFF

GlaxoSmithKline (GS71) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GS71 Analyst Ratings

Hold
15Ratings
3Buy9Hold3Sell
Based on 15 analysts giving stock ratings to GlaxoSmithKline in the past 3 months

GS71 Stock 12 Month Forecast

CHF23.03â–¼(-11.81% Downside)
Based on 15 Wall Street analysts offering 12 month price targets for GlaxoSmithKline in the last 3 months. The average price target is CHF 23.03 with a high forecast of CHF 33.21 and a low forecast of CHF 18.79. The average price target represents a -11.81% change from the last price of CHF 26.12.
Highest Price TargetCHF33.21Average Price TargetCHF23.03Lowest Price TargetCHF18.79

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CH:GS71
Price TargetArticle
CitiCHF23.21→CHF22.66hold-13.24%DownsideReiterated11/12/26
Deutsche Bank CHF22.11hold-15.35%DownsideReiterated11/10/26
BarclaysCHF19.34sell-25.94%DownsideReiterated11/03/26
Berenberg BankCHF24.31buy-6.90%DownsideReiterated11/03/26
J.P. MorganCHF18.79sell-28.06%DownsideReiterated11/03/26
BernsteinCHF33.27→CHF33.21buy27.15%UpsideReiterated11/02/26
Goldman SachsCHF20.56→CHF20.45hold-21.71%DownsideReiterated11/02/26
DZ BANK AG―hold―Reiterated10/30/26
Guggenheim Analyst forecast on CH:GS71Unknown AnalystNot RankedGuggenheimCHF22.92→CHF22.14hold-15.23%DownsideReiterated10/29/26
UBSCHF21.44hold-17.90%DownsideReiterated10/29/26
Bank of America SecuritiesCHF25.98hold-0.53%DownsideReiterated10/28/26
JefferiesCHF27.63buy5.80%UpsideReiterated10/28/26
RBC CapitalCHF0.22→CHF21.28hold-18.52%DownsideReiterated10/27/26
HSBCCHF20.56→CHF22.11hold-15.35%DownsideReiterated09/10/26
Morgan StanleyCHF19.34→CHF21.00sell-19.58%DownsideReiterated08/25/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
IMUXImmunic
QUITAchieve Life Sciences
COGTCogent Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GlaxoSmithKline

3 Months
Success Rate19/33 ratings generated profit
58%
Average Return
+1.42%

Copying Michael Leuchten's trades and holding each position for 3 Months would result in 57.58% of your transactions generating a profit, with an average return of +1.42% per trade.

1 Year
Success Rate22/33 ratings generated profit
67%
Average Return
+4.61%

Copying Michael Leuchten's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +4.61% per trade.

2 Years
Justin Smith
Justin SmithBernstein
Success Rate16/24 ratings generated profit
67%
Average Return
+9.18%

Copying Justin Smith's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +9.18% per trade.

GS71 Analyst Recommendation Trends

020406080Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for GS71
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy01122
Buy97677
Hold2825272525
Sell1619192017
Strong Sell00000
total5352535451

In the current month, GS71 has received 9 Buy Ratings, 25 Hold Ratings, and 17 Sell Ratings. GS71 average Analyst price target in the past 3 months is 23.03.

GS71 Financial Forecast

CHF-1CHF-0.5CHF0CHF0.5CHF1Q1 2026Q3 2026Q4 2026
HighCHF0.36
ConsensusCHF0.31
LowCHF0.27

GS71 Earnings Forecast

Next quarter’s earnings estimate for GS71 is CHF 0.31 with a range of CHF 0.27 to CHF 0.36. The previous quarter’s EPS was CHF 0.61. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

CHF8.5BCHF8.8BCHF9.2BCHF9.5BCHF9.9BQ1 2026Q3 2026Q4 2026
HighCHF9.91B
ConsensusCHF9.8B
LowCHF9.67B

GS71 Sales Forecast

Next quarter’s sales forecast for GS71 is CHF 9.80B with a range of CHF 9.67B to CHF 9.91B. The previous quarter’s sales results were CHF 9.86B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

GS71 Stock Forecast FAQ

What is CH:GS71’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is CHF23.03.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GlaxoSmithKline a Buy, Sell or Hold?
GlaxoSmithKline has a consensus rating of Hold, which is based on 3 buy ratings, 9 hold ratings and 3 sell ratings.
What is GlaxoSmithKline’s share price target?
The average share price target for GlaxoSmithKline is CHF23.03. This is based on 15 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF33.21, and the lowest forecast is CHF18.79. The average share price target represents a 11.81% decrease from the current price of CHF26.115.
What do analysts say about GlaxoSmithKline?
GlaxoSmithKline’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Street analysts.
How can I buy shares of GlaxoSmithKline?
To buy shares of CH:GS71, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.